Medical Marijuana

Unleashing the Therapeutic Potential of High CBD Seeds

Published

2 weeks ago

April 24, 2024

admin

In recent years, there has been a surge of interest in the medicinal properties of CBD (Cannabidiol), one of the prominent cannabinoids found in the cannabis plant. CBD is renowned for its soothing therapeutic properties and has been shown to offer a wide range of potential health benefits. High CBD seeds, which are now readily available on the market, have become a popular choice for individuals seeking natural remedies for various ailments.

What sets high CBD seeds apart is their impressive CBD content. These strains have been carefully curated to maximize the therapeutic potential of CBD, offering a rich blend of full-spectrum cannabinoids. Whether you’re looking to create your own CBD oil or simply want to experience the calming effects of CBD, these strains provide an excellent solution.

One of the key advantages of high CBD strains is their ability to alleviate anxiety. While some high THC strains can induce anxiety and paranoia, CBD has been shown to counteract these effects. By incorporating CBD weed into your routine, you can enjoy the benefits of cannabis without the unwanted side effects. Whether you prefer smoking a joint or using other consumption methods, adding CBD strains to the mix can provide a more soothing and balanced experience.

Amsterdam Marijuana Seeds, a reputable seed bank, offers a wide selection of high CBD strains. These seeds have been meticulously bred with medical cannabis in mind, ensuring that they meet the approved limits of regulatory agencies. As a result, they are perfectly legal in most parts of the world where medical cannabis is permitted. This means that individuals seeking natural remedies can access these seeds without any legal concerns.

Understanding CBD and Its Potential Medical Applications

To fully appreciate the benefits of high CBD seeds, it’s essential to understand CBD itself and its potential medical applications. Cannabidiol is a non-intoxicating component of the cannabis plant that has garnered significant attention from scientists and physicians alike. It is found in the resin, leaves, and stems of the cannabis plant, albeit in lesser quantities compared to THC.

CBD is just one of over 200 cannabinoids that can be extracted from the cannabis plant. However, it stands out for its beneficial and non-intoxicating properties. Its versatility as a pleiotropic drug allows it to produce various effects through multiple molecular pathways, making it a promising candidate for numerous medical conditions.

Scientific research has identified more than 65 conditions in which CBD may offer clinical intervention. These include heart diseases, pain management, treatment of inflammations and inflammatory conditions, anxiety and depression management, management of anxiety-related conditions such as PTSD and ADHD, management of autoimmune conditions like psoriasis and osteoporosis, and management of aging-related conditions like diabetes and insomnia.

While research into CBD’s efficacy is still ongoing, the scientific community has amassed substantial evidence supporting its potential therapeutic benefits. Recent studies have even explored CBD’s possible role in protecting the lungs of individuals exposed to the COVID-19 virus.

CBD interacts with the body’s Endocannabinoid System (ECS) to maintain balance and promote overall well-being. Its unique structure allows it to bind with cannabinoid receptors spread throughout the body, including the brain and central nervous system. By binding to these receptors, CBD exerts its manifold therapeutic effects, correcting imbalances and providing soothing therapy for a wide range of functions.

High CBD seeds are particularly well-suited for individuals who use CBD for medicinal purposes. These seeds offer a reliable and consistent source of CBD-rich strains that meet the legal requirements for medical cannabis. Whether you’re seeking relief from chronic pain, anxiety, inflammation, or other medical conditions, high CBD seeds can be a valuable tool in your holistic approach to wellness.

Exploring the Legality and Accessibility of High CBD Seeds

When it comes to the legality of CBD products, it’s important to note that regulations can vary from country to country. In many parts of the world where medical cannabis is legal, high CBD seeds are also perfectly legal. However, it’s crucial to familiarize yourself with the specific laws and regulations in your region to ensure compliance.

Amsterdam Marijuana Seeds offers a wide range of high CBD strains that cater to different needs and preferences. Their selection includes various seed genetics and types, allowing individuals to choose the strains that best suit their medicinal requirements. With a commitment to quality and compliance, Amsterdam Marijuana Seeds ensures that their high CBD seeds meet the highest standards of legality and potency.

For individuals seeking natural alternatives for their medical needs, high CBD seeds provide an excellent option. CBD has gained recognition for its potential therapeutic benefits, and high CBD strains offer a reliable and convenient way to access these benefits. By growing your own CBD-rich plants, you have control over the cultivation process and can ensure that you’re using high-quality, organic cannabis for your medicinal purposes.

It’s worth noting that while CBD has shown promising results in various clinical studies, the medical community is still exploring its full potential. Currently, there are only three cannabis-based drugs (one CBD and two THC) that have received FDA approval. However, this should not cast doubt on the prospects or efficacy of CBD as a viable treatment intervention. Ongoing research continues to shed light on CBD’s therapeutic properties and its role in improving existing treatment methodologies and discovering new interventions.

As the demand for CBD products continues to grow, it’s essential to choose reputable seed banks and suppliers. Amsterdam Marijuana Seeds has established a solid reputation in the industry, offering high-quality seeds and a wide selection of CBD strains. By purchasing from a trusted source, you can have peace of mind knowing that you’re obtaining authentic high CBD seeds that have been carefully bred for their medicinal properties.

In conclusion, high CBD seeds have gained popularity for their potential medicinal benefits and the ability to create a more balanced and soothing cannabis experience. Whether you’re seeking relief from anxiety, pain, inflammation, or other conditions, high CBD strains offer a natural alternative with minimal side effects. It’s important to stay informed about the legalities surrounding CBD in your region and to choose reliable suppliers like Amsterdam Marijuana Seeds to ensure product quality and compliance.

With the advancements in cannabis breeding techniques and ongoing scientific research, the future looks promising for CBD as a versatile and effective therapeutic compound. As more individuals discover the potential of high CBD seeds, they have the opportunity to incorporate the soothing benefits of CBD into their wellness routines and experience the holistic intervention of the entourage effect.

Frequently Asked Questions

What are the potential health benefits of CBD?

How can high CBD strains alleviate anxiety?

Are high CBD seeds legal and accessible for medicinal purposes?

Source link

Andrew Cooper

The Future Of Cannabis After Rescheduling

Published

2 days ago

May 3, 2024

admin

The Cannabis world is going through another big change with the potential of rescheduling – but what does it really mean?”

The Fresh Toast – The cannabis world is going through another major change, so what is the future of cannabis after rescheduling?

The Drug Enforcement Administration (DEA) is moving for cannabis to be rescheduled. The anticipated rescheduling follows the Department of Health & Human Services’ (HHS) August 2023 recommendation, based on scientific support for the rescheduling from the FDA, that cannabis be rescheduled under Schedule III of the Controlled Substances Act. Cannabis has remained a Schedule I substance since it was originally “temporarily” classified as such by the Controlled Substances Act of 1970. Schedule I drugs are defined as having no currently accepted medical use and a high potential for abuse, with other Schedule I drugs including heroin and LSD (despite cocaine, fentanyl, and other potentially dangerous drugs being in less restrictive drug schedules). The status of cannabis as a Schedule I drug has long been criticized, particularly as more and more U.S. states legalized cannabis for medical and recreational use.

From a consumer standpoint rescheduling will not actually legalize cannabis. At least not in a way forcing States in which cannabis is currently prohibited to immediately change course as a direct result of rescheduling. Instead, those States are likely to continue cannabis prohibition (though this momentous step may influence further states to legalize). Similarly, states with state-legal cannabis programs will likely not immediately change from a consumer perspective, although further regulation or even a reduction in product pricing due to cannabis no longer being subject to section 280E of the Internal Revenue Code (discussed in detail below) may soon follow.

There is more going on the business side with rescheduling. Falcon Rappaport & Berkman LLP has reviewed the process and outcomes.

Taxes

The most significant consequence of cannabis rescheduling will be the immediate removal of cannabis from the reach of I.R.C. Section 280E, which is arguably the greatest burden on state-legal cannabis operators. Section 280E prohibits cannabis businesses from writing off many business expenses when calculating their net profit, which has resulted in vastly higher taxes as compared to similar non-cannabis businesses. Instead, section 280E only permits a deduction for the Cost of Goods Sold (COGS) for any business trafficking in any controlled substances (i.e., drugs listed on Schedule I or Schedule II). Despite cannabis businesses operating under state-legal programs, they are considered “trafficking” and cannot take ordinary business deductions. Allowing cannabis businesses to deduct all ordinary and necessary business expenses, and not just COGS, will help to even the playing field with nearly every other legal business.

Federal Illegality

As discussed from a consumer standpoint, rescheduling cannabis does not affect the overall federal illegality of cannabis. This means that state-legal cannabis businesses will not automatically be federally legal, as their federal illegality will continue under Schedule III. While Schedule III drugs may be legally prescribed and sold under federal law, the various restrictions (such as requiring FDA approval of any such Schedule III drug and DEA registration of a distributor) mean that your average dispensary, even medical dispensaries, will still be federally non-compliant. For these same reasons, the reclassification to Schedule III does not mean that marijuana grown pursuant to state programs can be sold in interstate commerce. Marijuana products, even under Schedule III, are only federally legal if they are federally approved and there are only three FDA-approved cannabis-based drugs developed to date (Marinol, Epdiolex, and Syndros).

Intellectual Property & Cannabis Trademarks

The United States Patent and Trademark Office (USPTO), the agency tasked with examining federal trademark applications, has generally required use of a mark to be lawful under federal law in order to receive federal trademark registration under the U.S. Trademark Act (see Examination Guide 1-19). The federal illegality of cannabis has thus prevented trademark registration in connection with most cannabis products. Unfortunately, cannabis rescheduling will not remedy this issue. Even in Schedule III, cannabis products would have to be federally lawful, with lawful use of a Schedule III drug requiring FDA approval.

Entitlement to Federal Bankruptcy Protection

Currently, plant-touching cannabis companies are not entitled to federal bankruptcy protection. That is because the U.S. Bankruptcy Code requires that bankruptcy plans are “proposed in good-faith and not by any means forbidden by law.” Since even state-regulated cannabis companies violate the federal Controlled Substances Act (CSA), they are disqualified. Unfortunately, rescheduling to Schedule III of the CSA alone will not likely solve that barrier to bankruptcy. While some have argued otherwise, the fact is that to manufacture, distribute, or dispense a Schedule III Controlled Substance, businesses must be registered with the Drug Enforcement Administration (“DEA”). Any business or person not registered with the DEA is not authorized to manufacture, distribute, or dispense it. Meaning that violations would likely constitute an unlawful act under the CSA. Consequently, an attempt by the non-complying business to commence a voluntary petition seeking federal bankruptcy protection will likely result in a motion to dismiss the case by the U.S. Trustee’s Office.

However, in light of a recent trend among bankruptcy court’s in allowing ‘one-step-removed’ distribution of cannabis-related assets, federal rescheduling may very well result in a more liberalized approach to administering bankruptcy cases so that bankruptcy judges will be more willing to look past the issue of marijuana’s federal illegality.

Status Quo

There are several aspects of the existing cannabis industry which would not be immediately changed by rescheduling cannabis to Schedule III. Ongoing banking issues including the lack of access to standard commercial bank loans and lines of credit would likely persist; difficulties in processing cannabis transactions due to the reality that major credit card companies like Visa, Mastercard and others will likely still not service marijuana businesses; general federal illegality; and the criminalization of cannabis (and continued incarceration of certain offenders) in prohibitive states would remain following rescheduling.

While many had hoped for the de-scheduling of cannabis, the change in stance of the DEA, a longstanding adversary of cannabis reform, is no small feat.

Terran Cooper is a regular contributor to The Fresh Toast. He is part of Falcon Rappaport & Berkman LLP. This article was developed in part with the help of Andrew Cooper and Matthew Foreman.

Source link

Bob Groesbeck

What Can Consumers Expect From Marijuana Rescheduling

Published

3 days ago

May 3, 2024

admin

Most of the industry has been thrilled with the progress of rescheduling. But for the 40+ million who consume – what does it mean in real world terms?

The federal government took a big step toward rescheduling marijuana from a Schedule 1, which is a dangerous drug with zero medical benefits, to to Schedule III such as ketamine, Tylenol with codeine, and anabolic steroids. The industry is excited at the progress, the benefits will include the ability to have simple tax write off like any other normal mom and pop business. But what can consumers expect from marijuana rescheduling.

Two longer term benefits. With a Schedule III classification, medical researchers may find it easier to obtain the necessary approvals and funding for studies. With existing work, scientist have just began uncovering how the plant can help the body. By better understanding of the compound’s potential, better treatments will be available for a variety of health issue. The pharmaceutical industry, the major leader in research, stands to gain from increased research opportunities.

It also will move the medical industry closer into viewing cannabis as a legal, useful tool in treating patients. This could play a part in weaning physicians from using opioids for pain and using something developed from cannabis which is much less addictive.

a black and white photo of a machine

Another benefit is it allows legal businesses a bit more breathing room and some expansion, even in the short term. The hope is to push out the grey players who are causing issues. One which is the flow of premade products from maker to seller to consumer, currently – some cut corners and products are not quite the same as on traditional store shelves. Rescheduling will allow more oversight and safer products.

“Legalization represents a pivotal shift towards a safer, more accessible, and consumer-friendly cannabis market,” said, Bob Groesbeck, Co-CEO Planet 13. “Legalization would not only have significant economic implications but would also greatly benefit cannabis consumers. “With legal status ensuring that products undergo rigorous testing for safety and quality, consumers can confidently access products that meet stringent standards.

One benefit not seen in the near horizon is a lowering of prices. As a growing industry, most mom and pop need the extra cash to stabilize and grow. So while sales may happen, the benefit for the consumer is a healthy shop/product maker which will be around longer.

“Cannabis policy is a burning question with a small minority of the public but data show that in congressional campaigns, the vast majority (nearly 90% of candidates) never mention cannabis policy in public. That suggests that most voters are focused on different issues. Despite that, the current cannabis rescheduling petition before the federal government, and initiated by President Biden, is moving at lightning speed compared to every other cannabis rescheduling petition before it.” shared John Hudak, Director, Maine Office of Cannabis Policy.

Source link

banking

“A big deal”: What the feds’ move to reclassify marijuana means for Colorado cannabis

Published

4 days ago

May 1, 2024

admin

Cannabis advocates in Colorado cheered the Biden Administration’s reported move to reclassify marijuana and said the decision likely would reduce businesses’ tax burden significantly.

Industry leaders cautioned that such a move — if finalized — would not resolve some major challenges facing the industry, such as limited access to banking. But they pointed to the symbolic importance of preparations by the U.S. Drug Enforcement Administration to downgrade the substance’s drug classification.

A man pours cannabis into rolling papers as he prepares to roll a joint the Mile High 420 Festival in Civic Center Park in Denver, April 20, 2024. (Photo by Kevin Mohatt/Special to The Denver Post)

Read the rest of this story on DenverPost.com.

Source link